In adults with postacute sequelae of COVID-19, nirmatrelvir-ritonavir did not improve symptoms at 10 wk. Maki DG. Ann Intern Med 2024 Oct 1. doi: 10.7326/ANNALS-24-02172.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Maki DG. In adults with postacute sequelae of COVID-19, nirmatrelvir-ritonavir did not improve symptoms at 10 wk. Ann Intern Med 2024 Oct 1. doi: 10.7326/ANNALS-24-02172.
PMID: 39348701